

**Neuland**

Experience. Insight. Vision.

NEULAND LABORATORIES LIMITED

Registered Office : Sanali Info Park, 'A' Block, Ground Floor, 8-2-120/113, Road No. 2, Banjara Hills, Hyderabad - 500034

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2013**PART - I**

Amount in ₹ Million

Sl. No.	Particulars	Quarter Ended 30.06.2013 (Unaudited)	Quarter Ended 31.03.2013 (Unaudited)	Quarter Ended 30.06.2012 (Unaudited)	Year Ended 31.03.2013 (Audited)
1	Income from Operations				
	(a) Net Sales / Income from Operations	1,213.18	1,096.15	1,266.04	4,605.86
	(b) Other Operating Income	7.21	8.41	13.95	33.18
	Total Income from Operations (Net)	1,220.39	1,104.56	1,279.99	4,639.04
2	Expenses				
	(a) Consumption of Raw Materials	635.29	598.89	752.79	2,726.06
	(b) Changes in inventories of finished goods and work in process	46.57	26.26	45.72	(34.50)
	(c) Employee Benefit Expense	96.35	97.28	85.90	348.83
	(d) Depreciation	36.52	35.65	37.26	146.22
	(e) Manufacturing Expenses	122.94	149.57	110.65	482.98
	(f) Other Expenses	91.01	108.34	107.25	468.76
	Total Expenses	1,028.68	1,015.99	1,139.57	4,138.35
3	Profit from Operations before Foreign Exchange (gain) / loss and Finance Costs (1-2)	191.71	88.57	140.42	500.69
4	Foreign Exchange (gain) / loss (Net)	22.23	(4.71)	21.97	32.46
5	Profit from Operations before Finance Costs (3-4)	169.48	93.28	118.45	468.23
6	Finance Costs	59.01	64.94	79.68	313.30
7	Profit / (Loss) before Tax (5-6)	110.47	28.34	38.77	154.93
8	Tax Expense				
	(a) Current tax	21.05	5.84	7.97	30.19
	(b) Deferred Tax	32.36	34.02	-	41.87
	(c) MAT Credit entitlement	(21.05)	(53.50)	-	(53.50)
9	Net Profit / (Loss) for the period (7-8)	78.11	41.98	30.80	136.37
10	Paid-up Equity Share Capital	77.16	77.16	77.16	77.16
11	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year				898.33
12	Earnings per Share (EPS) (in ₹)				
	(a) Basic	10.22	5.49	4.03	17.84
	(b) Diluted	10.21	5.49	4.03	17.82

*Dr. Rao***Neuland Laboratories Limited**

Registered Office: Sanali Info Park, 'A' Block, Ground Floor, 8-2-120/113, Road no: 2, Banjara hills, Hyderabad - 500 034. AP, India. Tel : +91-40-30211600 Email: neuland@neulandlabs.com

Unit-1 : Survey No: 474, 347, 490/2, 488G & 489A, Bonthapally (V), Veerabhadraswamy Temple Road, Jinnaram (M), Medak Dist - 502313 AP, India, Tel : 08458-392724

Unit-2 : IDA, Pashamylaram, Isnapur Village, Patancheru (M), Medak Dist - 502 319 AP, India, Tel : 08455-302145



Neuland

Experience. Insight. Vision.

SEGMENT INFORMATION

SEGMENT REVENUE (NET SALES)

Particulars	Quarter Ended 30.06.2013 (Unaudited)	Quarter Ended 31.03.2013 (Unaudited)	Quarter Ended 30.06.2012 (Unaudited)	Year Ended 31.03.2013 (Audited)
(a) India	278.50	400.17	378.97	1,282.77
(b) Other than India	934.68	695.98	887.07	3,323.09
Total	1,213.18	1,096.15	1,266.04	4,605.86

PART - II

Sl. No.	Particulars	Quarter Ended 30.06.2013 (Unaudited)	Quarter Ended 31.03.2013 (Unaudited)	Quarter Ended 30.06.2012 (Unaudited)	Year Ended 31.03.2013 (Audited)
A	PARTICULARS OF SHARE HOLDING				
1	Public Shareholding				
	(a) Number of Shares	3,817,199	3,817,199	4,156,699	3,817,199
	(b) Percentage of Shareholding	49.93%	49.93%	54.37%	49.93%
2	Promoters and Promoter Group Shareholding				
	(a) Pledged / Encumbered				
	-Number of Shares	200,000	200,000	200,000	200,000
	-Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	5.22%	5.22%	5.73%	5.22%
	-Percentage of Shares (as a % of the total share capital of the Company)	2.62%	2.62%	2.62%	2.62%
	(b) Non-encumbered				
	-Number of Shares	3,627,779	3,627,779	3,288,279	3,627,779
	-Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	94.78%	94.78%	94.27%	94.78%
	-Percentage of Shares (as a % of the total share capital of the Company)	47.45%	47.45%	43.01%	47.45%

B INVESTOR COMPLIANTS

Particulars	Quarter Ended 30.06.2013
Pending at the beginning of the quarter	0
Received during the quarter	4
Disposed off during the quarter	3
Remaining unresolved at the end of the quarter	1



DR Rao

Neuland Laboratories Limited

Registered Office: Sanath Park, 'A' Block, Ground Floor, 8-2-120/113, Road no: 2, Banjara hills, Hyderabad - 500 034, AP, India. Tel : +91-40-30211600 Email: neuland@neulandlabs.com
 Unit-1: Survey No: 474, 347, 490/2, 488G & 489A, Bonthapally (V), Veerabhadraswamy Temple Road, Jinnaram (M), Medak Dist - 502313 AP, India, Tel : 08458-392724
 Unit-2 : IDA, Pashamylaram, Isnapur Village, Patancheru (M), Medak Dist - 502 319 AP, India, Tel : 08455-302145



Neuland

Experience. Insight. Vision.

NOTES:

- 1 The above unaudited financial results have been reviewed by the Audit Committee at their meeting held on August 1, 2013, and approved and taken on record at the Board of Directors meeting held on August 2, 2013.
- 2 EPS for the quarters is not annualised.
- 3 The Company's operations are predominantly related to the manufacture of Active Pharmaceutical Ingredients (API). As such there is only one primary reportable segment as per Accounting Standard - AS 17 "Segment Reporting".
- 4 Figures for the quarter ended March 31, 2013, are the balancing figures between the audited figures in respect of the financial year ended March 31, 2013 and the published year to date figures up to the quarter ended December 31, 2012.
- 5 Previous quarter / year figures have been regrouped wherever necessary.

Place: Hyderabad

Date: August 2, 2013



**By Order of the Board
For Neuland Laboratories Limited**

**Dr. D.R.Rao
Chairman & Managing Director**